

UMass Chan Medical School

eScholarship@UMassChan

---

GSBS Student Publications

Graduate School of Biomedical Sciences

---

2006-02-21

## Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers

Hanchen Li

*University of Massachusetts Medical School*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: [https://escholarship.umassmed.edu/gsbs\\_sp](https://escholarship.umassmed.edu/gsbs_sp)



Part of the [Gastroenterology Commons](#), and the [Life Sciences Commons](#)

---

### Repository Citation

Li H, Stoicov C, Rogers AB, Houghton J. (2006). Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. GSBS Student Publications. Retrieved from [https://escholarship.umassmed.edu/gsbs\\_sp/680](https://escholarship.umassmed.edu/gsbs_sp/680)

This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in GSBS Student Publications by an authorized administrator of eScholarship@UMassChan. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

# Stem cells and cancer: Evidence for bone marrow stem cells in epithelial cancers

Han-Chen Li, Calin Stoicov, Arlin B Rogers, JeanMarie Houghton

Han-Chen Li, Calin Stoicov, JeanMarie Houghton, Department of Medicine, Division of Gastroenterology; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, United States

Arlin B Rogers, Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139, United States

Correspondence to: JeanMarie Houghton, University of Massachusetts Medical School, LRB-Second Floor, Room 209, 364 Plantation Street, Worcester, MA 01605-2324, United States. jeanmarie.houghton@umassmed.edu  
Telephone: +1-508-856-6441

Received: 2005-06-10

Accepted: 2005-07-28

## Abstract

Cancer commonly arises at the sites of chronic inflammation and infection. Although this association has long been recognized, the reason has remained unclear. Within the gastrointestinal tract, there are many examples of inflammatory conditions associated with cancer, and these include reflux disease and Barrett's adenocarcinoma of the esophagus, Helicobacter infection and gastric cancer, inflammatory bowel disease and colorectal cancer and viral hepatitis leading to hepatocellular carcinoma. There are several mechanisms by which chronic inflammation has been postulated to lead to cancer which includes enhanced proliferation in an endless attempt to heal damage, the presence of a persistent inflammatory environment creating a pro-carcinogenic environment and more recently a role for engraftment of circulating marrow-derived stem cells which may contribute to the stromal components of the tumor as well as the tumor mass itself. Here we review the recent advances in our understanding of the contributions of circulating bone marrow-derived stem cells to the formation of tumors in animal models as well as in human beings.

© 2006 The WJG Press. All rights reserved.

**Key words:** Epithelial cancer; Stem cells

Li HC, Stoicov C, Rogers AB, Houghton J. Stem cells and cancer: Evidence for bone marrow stem cells in epithelial cancers. *World J Gastroenterol* 2006; 12(3): 363-371

<http://www.wjgnet.com/1007-9327/12/363.asp>

## INTRODUCTION

The association between cancer and inflammation has been recognized for over 2 000 years<sup>[1,2]</sup>. Virchow recognized that many tumors arise in a setting of chronic inflammation, and later, Dvorak aptly described cancer as "wounds that do not heal"<sup>[3]</sup>. It is estimated that up to 15% of cancers worldwide are associated with chronic infection<sup>[4]</sup> and there are many more examples throughout the body of cancer associated with inflammation of unclear etiology. Within the GI tract, examples include esophageal adenocarcinoma arising in the setting of Barrett's metaplasia, gastric cancer occurring secondary to Helicobacter infection, colorectal cancer occurring in longstanding inflammatory bowel disease and hepatocellular carcinoma secondary to viral hepatitis (Table 1). There are several mechanisms by which inflammation and a cycle of chronic injury/repair has been postulated to lead to cancer, including the push for continued proliferation, an abnormal inflamed-stromal environment, and more recently we recognize a role for engraftment of circulating marrow-derived stem cells, which may contribute to the stromal components of the tumor as well as the epithelial component of the tumor mass itself.

## INFLAMMATION: THE RELATIONSHIP BETWEEN TISSUE INJURY, REPAIR AND CANCER

Proliferation of cells alone is not sufficient to cause cancer, rather proliferation in the setting of altered growth signals from inflammatory cell infiltrates and DNA damaging agents released from infiltrating leukocytes promote malignant degeneration. Wound healing, which requires subversion of usual growth programs, mobilization and migration of cells and a heightened resistance to apoptosis, embodies all the properties of malignant cells with one exception, that is, healing is self limited. Successful wound healing results in restoration of tissue integrity and resolution of inflammation, reinstating homeostatic growth control. The tissue environments of longstanding unremitting chronic infection or idiopathic chronic inflammation are persistent states of inadequate wound healing. Within this setting, inflammatory cells produce highly reactive oxygen and nitrogen species, which interact with cellular DNA inducing point mutations, deletions or rearrangements. Usually DNA damage such as this triggers


Table 1 Infection and inflammation associated with cancers

Cause	Site
Chewing tobacco/oral irritation	Oral cancers
Smoking/chronic bronchitis	Lung
Asbestos	Mesothelioma
Reflux disease	Barretts' adenocarcinoma of the esophagus
Chronic Helicobacter infection	Gastric adenocarcinoma and lymphoma
Chronic pancreatitis	Pancreatic cancer
Opisthorchis sinensis infection (liver fluke)	Cholangiocarcinoma
Viral hepatitis	Hepatocellular carcinoma
Ulcerative colitis and Crohn's disease	Colorectal carcinoma
Human papilloma virus	Anogenital carcinomas
Schistosomiasis	Bladder cancer
Pelvic inflammatory disease	Ovarian cancer
Chronic osteomyelitis	Osteosarcoma
Chronic scar tissue	"Scar" cancer arising in the lung, skin and other areas of scarring


apoptosis. However, in areas of chronic inflammation and repair, growth programs are corrupted and the environment is poised to allow replication and survival of cells, which under normal situations would either be quiescent or lost to apoptosis. Allowing cells to continually divide in an environment conducive to DNA damage may result in the accumulation of genetic defects and the emergence of malignant cells.

Which cell is the target of malignant transformation has been the area of much debate. Original thought was that a terminally differentiated cell would acquire enough genetic damage to replicate endlessly. This would require multiple genetic alterations in key cell signaling cascades to allow autonomous growth. A more likely scenario, however, is that these cells would undergo apoptosis or be sloughed off as a normal part of organ turnover prior to "backing up" the differentiation ladder sufficiently to acquire independent growth. More recently, focus has been on tissue-derived stem cells as the source of cancer. Tissue stem cells possess several important features making them attractive candidates for malignant degeneration. These include long life span, relative apoptosis resistance and ability to replicate for extended periods of time. In the setting of chronic inflammation, progenitor or stem cells within the peripheral tissue are forced to undergo multiple rounds of cell division predisposing to the accumulation of mutations. While restricted progenitors or even differentiated cells can still become transformed, in most cases, it has been believed that early stem cells are the targets of transformation.

If one looks at areas of high proliferative capacity (high BrdU or PCNA staining in tissue) as the stem cell zone, then this theory of peripheral stem cells as the cells of origin of cancer must be reconciled with the fact that this supposed stem cell compartment is often the most damaged and depleted by agents thought to be carcinogens<sup>[5]</sup>. With chronic inflammation leading to atrophic changes attributed to peripheral stem cell exhaustion, the very cell thought to be transformed is lost - leading us to investigate if an alternate stem cell compartment is responsible for peripheral cancers arising in the setting of inflammation. In order to understand this concept, and why the bone marrow-derived stem cell (BMDC) is a "logical choice"



**Figure 1** A proposed model for the cancer stem cell. The cancer stem cell replicates itself asymmetrically, thus maintaining one daughter stem cell identical to itself. This remains in a relatively quiescent state. The asymmetric division also produces another daughter cell with a high proliferative rate which rapidly divides to sustain the tumor mass.



**Figure 2** Conventional versus stem cell-targeted chemotherapy. Conventional chemotherapy and radiotherapy targets rapidly dividing cells, and may shrink tumor mass substantially. However, the stem cell (gray), which is relatively quiescent, is not affected. Regrowth of tumor from surviving stem cell leads to regrowth of tumor and treatment failure. Chemotherapy targeted at the stem cell would remove the source of new cell growth, and allow residual cells within the tumor to be targeted with chemotherapy, differentiating agents or therapy aimed at inducing apoptosis, thus successfully eliminating the tumor.

for a cancer stem cell, we need to understand a few points about cancer stem cells, and BMDCs in general.

### Stem cells in cancer - cancer as an abnormal organ

A tumor mass can be compared to an abnormal organ; in that it is composed of a heterogeneous mixture of cell types and of cells possessing different proliferative capacities and different levels of differentiation. Tumor cells are admixed with fibroblasts, endothelial cells and inflammatory cells comprising the tumor stroma. This tumor stroma is being increasingly recognized as a critical contributor to malignant growth and survival of the tumor mass; however, stromal cells themselves are usually not malignant. Likewise, not all cells within a tumor are malignant - meaning not all cells can form tumors if transplanted at another site, or into a secondary host. In fact, the majority of cells within a tumor are incapable of independent growth and are readily susceptible to apoptosis. Only a small fraction of cells within a tumor are capable of independent growth, and fulfill the criteria described for cancer stem cells<sup>[6-8]</sup>. These cells have metastatic potential, form tumors in secondary hosts and are believed to be responsible for continual renewal of cells within the tumor mass. These cells are likely to proliferate slowly and asymmetrically,

self renewing the stem cell population and giving rise to daughter cells, which proliferate to sustain tumor growth (Figure 1). Conventional anti-cancer chemotherapy and radiotherapy target rapidly dividing daughter cells, affecting the bulk of the tumor mass, but leave the cancer stem cell intact, explaining the often rapid recurrence of tumor bulk, once therapy is stopped (Figure 2). At present, the most pressing issue for cancer research is to identify the cancer stem cell and exploit its unique characteristics with targeted therapies.

### **Bone marrow stem cells**

BMDCs are a heterogeneous group of cells isolated from the bone marrow which are capable of repopulating the hematopoietic system of a lethally irradiated immunologically compatible secondary host. These cells have been divided into at least two main categories; the hematopoietic and mesenchymal stem cells (MSC). Hematopoietic stem cells are traditionally regarded as the cells which give rise to the formed elements of the blood and have been used extensively in human bone marrow transplantation. Thus, hematopoietic stem cells have been extensively studied and defined with regard to surface markers, growth characteristics and repopulation potential<sup>[9]</sup>. Less well defined are the MSC. This term MSC, as defined in the literature, is the heterogeneous population of cells isolated as the adherent population, when total marrow is placed in culture<sup>[10]</sup>. These cells give rise to adipocyte, chondrocyte, cells of osteocyte lineages and the marrow mesenchyma, which is vital for optimal hematopoiesis<sup>[11-13]</sup>.

Work from multiple laboratories demonstrates surprising roles for marrow-derived stem cells in addition to hematopoiesis, stressing that the potential for differentiation may be much greater than originally believed. Markers defining cell subpopulations within the marrow are not standardized in these studies, making direct comparison of data between laboratories challenging; however, one thing remains consistent - cells within the bone marrow have a markedly greater differentiation potential than originally believed. For the purposes of this discussion, the term BMDCs will be broadly used to refer to cells derived from the marrow, and will encompass hematopoietic stem cells, MSC multipotent progenitor cells and whole marrow.

### ***In vitro* and *in vivo* studies-plasticity of BMDCs**


Multiple and elegant studies from independent groups have shown quite clearly that bone marrow stem cells can differentiate along multiple diverse lineage pathways<sup>[14-17]</sup>. These findings challenge the conventional view that bone marrow stem cells give rise only to the marrow mesenchyma or formed elements in the peripheral blood. *In vitro*, BMDCs have been shown to differentiate at the single cell level and acquire characteristics of mesoderm, neuroectoderm and endoderm<sup>[15,16]</sup>. These cells appear to use culture environmental factors to guide lineage decisions. Strikingly, *in vivo* studies in the mouse model have confirmed this plasticity. Elegant studies utilizing transplanted single cells demonstrate differentiation along multiple lineages, supporting a central role for the local tissue environment in dictating differentiation of stem cells, confirming that a single cell is multipotent, and supporting the assertion

that experimental findings demonstrating multiple cell lineage differentiation is not due to circulating tissue specific progenitor cells, but rather to a single multipotent cell. In these studies, multiple types of epithelial cells have been shown to be derived from BMDCs including epithelium of the lung, gastrointestinal tract and skin after transplantation of a single bone marrow-derived stem cell<sup>[14]</sup>. This is not a transient event, as cells can be recovered nearly a year after transplantation. In the gastrointestinal tract, engrafted cells are seen as isolated epithelial cells in the gastric pits of the stomach, the small intestinal villi, the colonic crypt, and rarely in the esophagus. Under these experimental conditions, cells were recovered as single differentiated epithelial cells, and did not appear to engraft into the stem cell niche as clonal expansion was not seen. Infusion of labeled BMDCs into a non-irradiated host, also led to the engraftment (*albeit* to a lesser degree) and differentiation as epithelial cells of the liver, lung and gut in a similar pattern to that seen with marrow ablation and transplantation<sup>[15]</sup>, demonstrating that engraftment and differentiation are true physiological events and not merely artifacts of irradiation and experimental manipulation. While epithelial cell damage is not necessary for engraftment, studies support the notion that damage to the epithelium increases engraftment.

The mechanism by which the marrow-derived cells acquire the appropriate phenotype of epithelial cells is not known, with evidence supporting both direct differentiation or fusion with a peripheral cell<sup>[18-21]</sup>. The method of engraftment and differentiation may be specific to the individual tissues and/or may depend on the mechanism of injury inducing engraftment. Irrespective of the mechanism involved, BMDCs have been shown to engraft and take on the function of cells within the peripheral tissues<sup>[18-24]</sup>.

## **HUMAN STUDIES - EVIDENCE FOR PLASTICITY OF BMDCS IN PATIENTS TRANSPLANTED WITH GENDER MISMATCHED BONE MARROW**

Human studies have confirmed that plasticity of BMDCs is not restricted to mice, and may be a physiologically relevant phenomenon in man as well. Studies, examining peripheral tissue of female patients transplanted with bone marrow derived from male donors, have shown that BMDCs from the donor can differentiate into skin, gut epithelium and mature hepatocytes<sup>[25,26]</sup>. Identification of the Y chromosome in cells of these tissues confirms that BMDCs can substantially repopulate the GI tract epithelium<sup>[26]</sup>, and this repopulation does not appear to be a rare event. Patients in these studies have some level of graft-versus-host disease, and the level of inflammation in the tissue correlates with the level of donor cell engraftment. These findings are consistent with the data derived from murine studies and suggest the inflammatory environment is crucial for optimal engraftment and differentiation of BMDCs. The fact that BMDCs have the capacity to differentiate along organ-specific lineages appropriate for the organ of engraftment, and are found in increasing num-



**Figure 3** An experimental mouse model for bone marrow transplantation and *H. felis*-induced gastric carcinoma.

bers during chronic inflammation (a condition associated with cancer), places these cells “in the right place, at the right time” to be candidates for the cancer stem cell.

#### Similarities between BMDCs and cancer cells

In addition to what appears to be of immense plasticity of cells within the bone marrow, BMDCs have other traits which make them attractive candidates for cancer stem cells. BMDCs have the capacity for self renewal, are long lived, are chemoresistant, and may be inherently mutagenic<sup>[27-30]</sup>. Intriguing is the fact that similar growth regulators and control mechanisms are involved in both cancer and stem cell maintenance. For example, proteins from the polycomb group, the epigenetic chromatin modifiers, are involved in both cancer development and maintenance of embryonic and adult stem cells<sup>[31]</sup>. Also, pathways used by bone marrow stem cells for trafficking appear to be exploited by tumor cells for metastasis<sup>[32]</sup>. For instance, chemokines and cytokines produced during chronic inflammation (such as SDF-1) influence the behavior and migration of cancer cells. These are the same chemokines and cytokines responsible for physiological stem cells homing back to the marrow cavity<sup>[33-37]</sup>. Identification of bone marrow stromal cell-derived growth inhibitor as a potent inhibitor of breast cancer cell migration, and the capability of this protein to induce cell cycle arrest and apoptosis in breast cancer stem cells further supports the use of similar growth mechanisms between stem and cancer cells<sup>[38]</sup>. Inflammation of the GI tract is associated with IL-6 and IL-8 production which initiate neutrophil infiltration<sup>[40]</sup>. Interestingly, IL-6 is also chemotactic for MSC<sup>[34]</sup>. Other cytokines and chemokines prominent in the setting of mucosal inflammation such as VEGF and MIP-1 $\alpha$  are also chemoattractants for MSC<sup>[34,35]</sup>. Receptors such as CXCR 2 and 4 are found on both cancer cells and stem cells, and influence the homing of stem cells, or invasion/metastases of cancer cells, suggesting a link between the two populations of cells. One might suppose that a mechanism similar to that used to regulate BMDC circulation and homing back to areas of bone may also facilitate migration and engraftment of BMDCs into peripheral tissues as a result


of chronic inflammation, if the peripheral tissue secretes the appropriate homing signals.

Additionally, immune escape has long been a perplexing property of cancer cells; MSCs have unique immunological properties in that they are not immunogenic, they do not stimulate alloreactivity, and they escape lysis by cytotoxic T cells and natural killer cells<sup>[40]</sup>. This inherent ability to evade immune recognition may explain why many cancer cells evade the host immune response.

#### BMDCs as the origin of epithelial cancer: helicobacter induced gastric cancer as a model system

We reasoned that BMDCs, as the ultimate uncommitted adult stem cell, might represent the ideal candidate for transformation, if placed in a favorable environment. We used the well-described *H. felis*/C57BL/6 mouse model of gastric cancer to test this theory<sup>[41]</sup>. This model is optimal for studying the role of stem cells in inflammatory-mediated cancers because C57BL/6 mice do not develop gastric cancer under controlled conditions. With *Helicobacter* infection, however, the gastric mucosa progresses through a series of changes including metaplasia and dysplasia, culminating in gastrointestinal intraepithelial neoplasia (GIN)<sup>[42]</sup> by 12-15 mo of infection, thus reiterating human disease, where gastric cancer in the absence of *Helicobacter* infection is unusual, while longstanding infection carries a significant (up to 1-3%) risk of gastric cancer<sup>[43-48]</sup>. In order to test the role for BMDCs in gastric cancer (Figure 3), C57BL/6J mice were myeloablated and transplanted with gender-mismatched bone marrow from mice that expressed a non-mammalian beta-galactosidase enzyme [C57BL/6J *Gtrosa26* (ROSA 26)], mice that expressed green fluorescent protein [C57BL/6J *-beta-actin-EGFP* (GFP)], or control C57BL/6J litter mates. Engraftment of ROSA26 BMDCs into the gastric mucosa was confirmed by several independent methods including detecting enzyme activity, specific B-galactosidase immunohistochemistry (IHC, two cytoplasmic markers) (Figures 4 and 5), and detection of LacZNeo fusion gene sequence (nuclear marker) by PCR within beta-galactosidase positive gastric glands isolated by laser capture microscopy. In those mice transplanted with GFP marrow, GFP was detected by fluorescence activated cell sorting of cytokeratin positive-single cell preparations, and GFP immunohistochemistry of tissue sections. X and Y chromosome fluorescent *in situ* hybridization (X and Y-FISH) was used as an additional means to detect BMDCs in gender mismatched transplants<sup>[41]</sup>.

As expected, acute *Helicobacter* infection was associated with an influx of bone marrow-derived inflammatory cells (Figure 4A - blue staining) into the tissue. At early time points, we did not detect any engraftment or differentiation of BMDCs to an epithelial cell phenotype. At 20 wk of infection, rare glands entirely replaced by BMDCs were isolated, suggesting that engraftment into the stem cell niche had occurred. These findings were more pronounced at 30 wk, where antralized glands and metaplastic cells at the squamocolumnar junction were entirely replaced by marrow-derived cells (Figures 4D and E). The severity of intraepithelial dysplasia increased over time, and by one year of infection, most mice developed invasive neoplastic glands. All of the intraepithelial neoplasia in mice infected



**Figure 4** Engraftment of donor-derived ROSA-26 marrow by x-gal staining. **A:** Mice transplanted with ROSA 26 marrow and infected with *H. felis* for 4 wk had donor-derived leukocytes (blue) infiltrating the gastric mucosa, and no engraftment into gland structures. **B and C:** A higher power view reveals myocytes and myofibroblasts in the sub-mucosal tissue adjacent to vascular structures (arrows). **D:** After 30 wk of infection, marked architectural distortion is seen with antralization and appearance of metaplastic glands. Entire gland structures are derived from donor marrow (blue staining). Gland shown in panel D (arrow) is shown at higher power in **E**.


for 12-16 mo rose from donor marrow cells, strongly suggesting an inherent vulnerability of this population of cells to malignant progression. Progressive parietal and chief cell loss is a hallmark of chronic *Helicobacter* infection. Of the few parietal or chief cells which we isolated from the infected mice, none were derived from the bone marrow, strongly suggesting that marrow cells do not differentiate toward the parietal or chief cell phenotype under the experimental conditions that were used<sup>[41]</sup>.

Normal healing of the gastric mucosa after iatrogenic ulceration likewise did not require BMDCs<sup>[41]</sup>, nor did loss of specific cell lineages, such as targeted ablation of parietal cells, lead to marrow engraftment<sup>[41]</sup>. Rather, it seems that long standing inflammation and inflammatory mediated damage to the epithelium is required - an environment strongly linked to the development of cancer in many settings. In our *Helicobacter*-gastric cancer model, infection and inflammation reached a plateau at 8 wk; however, engraftment was not apparent until 20 wk, suggesting that events other than increased inflammation are responsible for engraftment. Between 8 and 20 wk, there is loss of the oxyntic glands, and a restructuring of the gastric architecture to include metaplastic cell lineages, re-


flecting the effects of an abnormal tissue milieu on rapidly proliferating cells<sup>[49]</sup>. Once engraftment began, however, the number of bone marrow-derived glands increased dramatically, suggesting that a threshold for recruitment had been reached<sup>[41]</sup>.

In addition to epithelial cells within the tumor, BMDCs also comprise a subset of cells within the tumor stroma and within seemingly uninvolved epithelium and subepithelial spaces adjacent to the tumors. We have recovered adipocytes (Figure 5C), fibroblast, endothelial cells and myofibroblasts (Figures 4 B and C) derived from bone marrow precursors in areas adjacent to dysplasia and neoplasia.

Based on these experiments, we have proposed a new paradigm for epithelial cancer (Figure 6). Chronic tissue inflammation leads to tissue injury and with time, to tissue stem cell failure. Peripheral stem cell failure leads to recruitment and permanent engraftment of BMDCs into the tissue stem cell niche, where the BMDCs essentially take over the function of the tissue stem cell. In the setting of inflammation, specifically with Th1 type cytokines and an abnormal tissue environment (for example, one lacking chief and parietal cells), the BMDCs initiate differentia-



**Figure 5** Immunohistochemistry for bacterial beta-galactosidase confirms uniform signal in gastrointestinal neoplasia. Mice developed severe dysplasia and intraepithelial neoplasia derived from donor marrow, 12-15 mo after infection with *H. felis* (A) and (B). Immunohistochemistry for bacterial beta-galactosidase demonstrates cytoplasmic staining in dysplastic glands. A population of adipocytes in the submucosa are also stained for beta-galactosidase (arrow).



**Figure 6** A new paradigm proposed for epithelial cancer.

tion, but fail to regulate growth programs appropriately and progresses through stages of metaplasia and dysplasia. We speculate that the inappropriate retention of primitive growth programs in a stem cell forced to replicate may permit survival despite otherwise lethal mutations, thus allowing transformation. This new model brings together previously unexplained observations regarding the behavior of cancer, and presupposes that properties inherent to cancer such as their resistance to apoptosis, their unlimited growth potential and their ability for local spread and distant metastasis are fundamental to the origin of the cell, rather than traits acquired. The concept of cancer initiation and promotion can also be viewed within the context of this model. Initiation may represent BMDCs trafficking into the stem cell niche as a result of tissue stem cell damage. In the absence of continued inflammation and injury, these engrafted cells may behave in a way indistinguishable from endogenous tissue stem cells. Promotion may represent an additional stimulus received at a later time that allows sustained proliferation of BMDCs and transformation.

#### ***In vitro* experiments and animal models supporting the BMDC-epithelial cancer model**

In addition to the *Helicobacter*-gastric cancer model, other studies have begun to address the role of BMDCs in cancer using various *in vitro* and *in vivo* models. For example, BMDCs have been shown to localize to a known stem cell

niche within the epidermis known as the CD34 positive bulge region of the hair follicle, and clonally expand to repopulate portions of the epidermis, functioning as an epidermal stem cell<sup>[50]</sup>. Similar to our findings, engraftment of BMDCs to the stem cell niche is dramatically increased with injury severe enough to deplete peripheral stem cells in the region. However, these are short-term studies. Longer term studies utilizing carcinogen exposure will determine the eventual fate of these BMDCs, and determine if BMDCs in the stem cell niche behave differently from peripheral stem cells occupying the same niche. It is intriguing, however, to speculate the ultimate fate of these stem cells given the prevalence of BMDC-skin carcinoma in solid organ recipients (see below).

In addition to residing in the epithelial stem cell niche, bone marrow-derived myofibroblasts have been recovered within the colonic subepithelial compartments in both mice and human beings<sup>[51,52]</sup>. Interestingly, Direkze *et al.* observed that in the IL-10 knockout mouse model of colitis, up to 45% of subepithelial myofibroblasts were marrow derived<sup>[52]</sup>, suggesting that in the setting of chronic inflammation, damaged tissue is replaced by BMDCs. When the same group looked at tumor-associated myofibroblasts and fibroblasts, they also found a significant portion of these cells derived from bone marrow cells<sup>[51]</sup>. It is not clear from these data, if tumors recruit bone marrow cells into the stromal compartment or if resident myofibroblasts and fibroblasts derived from marrow contribute to tumor formation because of abnormal signaling behavior.

Adenocarcinoma of the distal esophagus (Barrett's adenocarcinoma) results from reflux-induced mucosal damage followed by healing with a metaplastic intestinal cell lineage. This intestinal metaplasia is prone to malignant degeneration and is another ideal model to test the role of BMDCs in inflammatory-mediated cancers. Using a rat model of Barrett's metaplasia, a significant contribution of BMDCs to the stroma and the metaplastic epithelium has been demonstrated, supporting a role for BMDCs in these pre-neoplastic lesions<sup>[53]</sup>. Though these findings have only been reported in an abstract form so far, this information is especially exciting because it provides evidence of direct BMDC involvement in carcinogenesis from both an additional species (rat) and tissue type (esophagus), providing

further support for our BMDC-epithelial cancer model.

### **Human data supporting the BMDC-epithelial cancer model**

In human beings, the incidence of solid tumors is significantly increased following bone marrow transplantation<sup>[54]</sup> and may be related to persistent chronic inflammation of graft *vs.* host disease. The data on BMDCs in human cancers, however, have been conflicting. First, it is difficult to examine the contribution of donor marrow to tumor formation in human beings because of a paucity of cell markers to consistently identify autologous BMDCs or donor cells after BM transplantation. The most reliable marker we have to date is identification of the sex chromosomes in sex mismatched transplants. However, there are inherent difficulties with using Y-chromosome identification. X/Y fluorescent *in situ* hybridization (FISH) analysis of archived tumors is estimated to miss more than 50% of Y-positive cells due to sectioning bias, where only a portion of the nucleus and thus only a portion of the chromosomes are included in the tissue section. Additionally, females with a history of carrying a male fetus may show peripheral blood chimerism confounding interpretation of data, and eliminating this population from the study. Also, tumors identified within a short time after transplant may reflect the effects of immunosuppression on previously undetected early malignancy and not newly formed tumors, and may explain why some studies conclude tumors in these patients are host derived<sup>[55]</sup>, while other studies demonstrate a definite contribution of donor's-BMDCs<sup>[56]</sup>. Studies utilizing larger numbers of patients followed for longer periods of time will better address this new and controversial area, and determine if the BMDCs are confined to the stroma, involved in angiogenesis or constitute the epithelial component of the tumor mass in human beings.

In addition to patients receiving bone marrow transplants, recipients of solid organ transplants also have a higher incidence of secondary malignancy. Interestingly, in solid organ transplant recipients, hematopoietic cells of donor origin are often found in the circulation, indicating that hematopoietic stem cells are transferred with the transplanted organ<sup>[57,58]</sup>. These transferred stem cells have been shown to give rise to Kaposi sarcoma (KS), a vascular tumor<sup>[59]</sup>, and skin carcinoma<sup>[60]</sup>. The detected KS lesions occurred distal to the graft site, and formed presumably via mobilization of donor progenitor cells with subsequent transformation at a distant site. Donor-derived stem cells contribute to skin carcinomas, and have been recovered as components of squamous cell carcinoma, basal cell carcinoma, actinic keratosis, keratoacanthomas and benign cutaneous lesions<sup>[60]</sup>, attesting to the great potential for abnormal differentiation of these cells. BMDCs as terminally differentiated cells in other organs including hepatic endothelial cells, hepatocytes and biliary epithelial cells<sup>[61]</sup>, suggesting that these cells may play a role in transformation within these organs as well, if subjected to the appropriate environmental conditions.

### **CONCLUSION**

One of the greatest and most elusive challenges in cancer biology has been to identify the cellular origin of cancer.

We have identified the bone marrow stem cell as the cell of origin of Helicobacter-induced gastric cancer in a mouse model, radically altering our current view of gastric cancer formation in particular, and of inflammation-mediated cancers in general. The concept of BMDC plasticity is being increasingly recognized and validated by independent groups. Our recent observation that BMDCs are the origin of Helicobacter-induced gastric cancer<sup>[41]</sup> combined with supporting observations of BMDCs in other tumors such as benign and malignant tumors of the skin<sup>[60]</sup>, Kaposi sarcoma<sup>[59]</sup> Barretts' adenocarcinoma of the esophagus<sup>[53]</sup> as well as demonstration of BMDCs as constituents of tumor stroma and tumor vascular structures<sup>[52-56]</sup> suggests exciting approaches for cancer therapy. If the propensity for BMDCs to transform is based on inappropriate regulation of immature growth programs, with growth programs left "turned on" rather than the previously held concept of mutation driven-reactivation of programs, can we target these pathways? Undoubtedly, genetic mutations have occurred which are irreversible; but if we can target and switch off inappropriately activated growth cascades, perhaps we can push these damaged cells into apoptosis or enhance the sensitivity to conventional chemo- and radiotherapy. These approaches may lead to novel and more efficacious cancer therapy.

Presently, our laboratory is involved in identifying the cell population within the bone marrow capable of cancer formation as well as defining the homing and differentiation signals which allow these cells to access to gastric mucosa, and to differentiate as metaplastic and dysplastic cells. Studies designed to determine if fusion is a means of bone marrow cell integration into gastric mucosa and gastric cancer are underway. The applicability of these findings to other epithelial cancers will be tested as well as our ability to control the growth of these cells by manipulations of the local tissue environment. These efforts are aimed at identifying cell-specific targets for chemotherapy. Findings from these studies will radically alter our approach to the treatment of gastric cancer as well as other solid tumors, and offer hope for improved survival and potential cure.

### **REFERENCES**

- 1 **Balkwill F**, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; **357**: 539-545
- 2 **Coussens LM**, Werb Z. Inflammation and cancer. *Nature* 2002; **420**: 860-867
- 3 **Dvorak HF**. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N Engl J Med* 1986; **315**: 1650-1659
- 4 **Kuper H**, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. *J Intern Med* 2000; **248**: 171-183
- 5 **Potten CS**, Booth C, Hargreaves D. The small intestine as a model for evaluating adult tissue stem cell drug targets. *Cell Prolif* 2003; **36**: 115-129
- 6 **BRUCE WR**, VAN DER GAAG H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. *Nature* 1963; **199**: 79-80
- 7 **Hamburger AW**, Salmon SE. Primary bioassay of human tumor stem cells. *Science* 1977; **197**: 461-463
- 8 **Park CH**, Bergsagel DE, McCulloch EA. Mouse myeloma tumor stem cells: a primary cell culture assay. *J Natl Cancer Inst*



- 1971; **46**: 411-422
- 9 **Baum CM**, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. *Proc Natl Acad Sci USA* 1992; **89**: 2804-2808
- 10 **Baddoo M**, Hill K, Wilkinson R, Gaupp D, Hughes C, Kopen GC, Phinney DG. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. *J Cell Biochem* 2003; **89**: 1235-1249
- 11 **Bensidhoum M**, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L, Bouchet S, Bertho JM, Gourmelon P, Aigueperse J, Charbord P, Gorin NC, Thierry D, Lopez M. Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. *Blood* 2004; **103**: 3313-3319
- 12 **Kassem M**. Mesenchymal stem cells: biological characteristics and potential clinical applications. *Cloning Stem Cells*. 2004; **6**: 369-374
- 13 **Bai X**, Xiao Z, Pan Y, Hu J, Pohl J, Wen J, Li L. Cartilage-derived morphogenetic protein-1 promotes the differentiation of mesenchymal stem cells into chondrocytes. *Biochem Biophys Res Commun* 2004; **325**: 453-460
- 14 **Krause DS**, Theise ND, Collector ML, Henegariu O, Hwang S, Gardner R, Neutzel S, Sharkis SJ. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. *Cell* 2001; **105**: 369-377
- 15 **Jiang Y**, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 2002; **418**: 41-49
- 16 **LaBarge MA**, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. *Cell* 2002; **111**: 589-601
- 17 **Petersen BE**, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP. Bone marrow as a potential source of hepatic oval cells. *Science* 1999; **284**: 1168-1170
- 18 **Newsome PN**, Johannessen I, Boyle S, Dalakas E, McAulay KA, Samuel K, Rae F, Forrester L, Turner ML, Hayes PC, Harrison DJ, Bickmore WA, Plevris JN. Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. *Gastroenterology* 2003; **124**: 1891-1900
- 19 **Harris RG**, Herzog EL, Bruscia EM, Grove JE, Van Arnam JS, Krause DS. Lack of a fusion requirement for development of bone marrow-derived epithelia. *Science* 2004; **305**: 90-93
- 20 **Vassilopoulos G**, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. *Nature* 2003; **422**: 901-904
- 21 **Wang X**, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M. Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature* 2003; **422**: 897-901
- 22 **Camargo FD**, Green R, Capetanaki Y, Jackson KA, Goodell MA. Single hematopoietic stem cells generate skeletal muscle through myeloid intermediates. *Nat Med* 2003; **9**: 1520-1527
- 23 **LaBarge MA**, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. *Cell* 2002; **111**: 589-601
- 24 **Shimizu K**, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. *Nat Med* 2001; **7**: 738-741
- 25 **Yeh ET**, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+ enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells *in vivo*. *Circulation* 2003; **108**: 2070-2073
- 26 **Korbling M**, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. *N Engl J Med* 2002; **346**: 738-746
- 27 **Serakinci N**, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T, Kassem M. Adult human mesenchymal stem cell as a target for neoplastic transformation. *Oncogene* 2004; **23**: 5095-5098
- 28 **Rubio D**, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. Spontaneous human adult stem cell transformation. *Cancer Res* 2005; **65**: 3035-3039
- 29 **Xu W**, Qian H, Zhu W, Chen Y, Shao Q, Sun X, Hu J, Han C, Zhang X. A novel tumor cell line cloned from mutated human embryonic bone marrow mesenchymal stem cells. *Oncol Rep* 2004; **12**: 501-508
- 30 **Burns JS**, Abdallah BM, Guldberg P, Rygaard J, Schroder HD, Kassem M. Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells. *Cancer Res* 2005; **65**: 3126-3135
- 31 **Valk-Lingbeek ME**, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. *Cell* 2004; **118**: 409-418
- 32 **Liang Z**, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. *Cancer Res* 2004; **64**: 4302-4308
- 33 **Lyden D**, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nat Med* 2001; **7**: 1194-1201
- 34 **Rodriguez Mdel C**, Bernad A, Aracil M. Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support. *Blood* 2004; **103**: 3349-3354
- 35 **Toh K**, Kukita T, Wu Z, Kukita A, Sandra F, Tang QY, Nomiyama H, Iijima T. Possible involvement of MIP-1alpha in the recruitment of osteoclast progenitors to the distal tibia in rats with adjuvant-induced arthritis. *Lab Invest* 2004; **84**: 1092-1102
- 36 **El-Omar EM**, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow WH. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. *Gastroenterology* 2003; **124**: 1193-1201
- 37 **Janowska-Wieczorek A**, Marquez LA, Nabholz JM, Cabuhat ML, Montano J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. *Blood* 1999; **93**: 3379-3390
- 38 **Wang T**, Xia D, Li N, Wang C, Chen T, Wan T, Chen G, Cao X. Bone marrow stromal cell-derived growth inhibitor inhibits growth and migration of breast cancer cells via induction of cell cycle arrest and apoptosis. *J Biol Chem* 2005; **280**: 4374-4382
- 39 **Suzuki T**, Ina K, Nishiwaki T, Tsuzuki T, Okada T, Furuta R, Nobata K, Ando T, Kusugami K, Goto H. Differential roles of interleukin-1beta and interleukin-8 in neutrophil transendothelial migration in patients with *Helicobacter pylori* infection. *Scand J Gastroenterol* 2004; **39**: 313-321
- 40 **Reya T**, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature* 2001; **414**: 105-111
- 41 **Houghton J**, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. *Science* 2004; **306**: 1568-1571
- 42 **Boivin GP**, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, Pitot HC, Halberg RB, Itzkowitz SH, Groden J, Coffey RJ. Pathology of mouse models of intestinal cancer: consensus report and recommendations. *Gastroenterology* 2003; **124**: 762-777
- 43 **Nomura A**, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GL, Blaser MJ. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991; **325**: 1132-1136
- 44 **Correa P**. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992;

- 52: 6735-6740
- 45 Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983; **1**: 1273-1275
- 46 **Forman D**, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, Sitas F. Association between infection with *Helicobacter pylori* and risk of gastric cancer: evidence from a prospective investigation. *BMJ* 1991; **302**: 1302-1305
- 47 **Parsonnet J**, Friedman GD, Vandersteen DP, Chang Y, Vogelstein JH, Orentreich N, Sibley RK. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991; **325**: 1127-1131
- 48 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789
- 49 **Cai X**, Carlson J, Stoicov C, Li H, Wang TC, Houghton J. *Helicobacter felis* eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. *Gastroenterology* 2005; **128**: 1937-1952
- 50 **Brittan M**, Braun KM, Reynolds LE, Conti FJ, Reynolds AR, Poulson R, Alison MR, Wright NA, Hodivala-Dilke KM. Bone marrow cells engraft within the epidermis and proliferate *in vivo* with no evidence of cell fusion. *J Pathol* 2005; **205**: 1-13
- 51 **Bamba S**, Otto WR, Lee CY, Brittan M, Preston SL, Wright NA. The contribution of bone marrow to colonic subepithelial myofibroblasts in interleukin-10 knock out mice. *Gastroenterology* 2005; **128**: A490
- 52 **Direkze NC**, Hodivala-Dilke K, Jeffery R, Hunt T, Poulson R, Oukrif D, Alison MR, Wright NA. Bone marrow contribution to tumor associated myofibroblasts and fibroblasts. *Cancer Res* 2004; **64**: 8492-8495
- 53 **Sarosi GA**, Brown G, Jaiswal K, Lee E, Crook T, Souza R, Zou Y, Shat J, Spechler S. Reflux-Damaged Esophageal Epithelium Is Replaced By Cells Derived from the Bone Marrow in a Rat Model of Barrett's Esophagus. *Gastroenterology* 2004; **126**: A35
- 54 **Ades L**, Guardiola P, Socie G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. *Blood Rev* 2002; **16**: 135-146
- 55 **Au WY**, Chan EC, Pang A, Lie AK, Liang R, Yuen AP, Shek TW, Kwong YL. Nonhematologic malignancies after allogeneic hematopoietic stem cell transplantation: incidence and molecular monitoring. *Bone Marrow Transplant* 2004; **34**: 981-985
- 56 **Peters BA**, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. *Nat Med* 2005; **11**: 261-262
- 57 **Suberbielle C**, Caillat-Zucman S, Legendre C, Bodemer C, Noel LH, Kreis H, Bach JF. Peripheral microchimerism in long-term cadaveric-kidney allograft recipients. *Lancet* 1994; **343**: 1468-1469
- 58 **Sivasai KS**, Alevy YG, Duffy BF, Brennan DC, Singer GG, Shenoy S, Lowell JA, Howard T, Mohanakumar T. Peripheral blood microchimerism in human liver and renal transplant recipients: rejection despite donor-specific chimerism. *Transplantation* 1997; **64**: 427-432
- 59 **Barozzi P**, Luppi M, Facchetti F, Mecucci C, Alu M, Sarid R, Rasini V, Ravazzini L, Rossi E, Festa S, Crescenzi B, Wolf DG, Schulz TF, Torelli G. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. *Nat Med* 2003; **9**: 554-561
- 60 **Aractingi S**, Kanitakis J, Euvrard S, Le Danff C, Peguillet I, Khosrotehrani K, Lantz O, Carosella ED. Skin carcinoma arising from donor cells in a kidney transplant recipient. *Cancer Res* 2005; **65**: 1755-1760
- 61 **Hove WR**, van Hoek B, Bajema IM, Ringers J, van Krieken JH, Lagaaij EL. Extensive chimerism in liver transplants: vascular endothelium, bile duct epithelium, and hepatocytes. *Liver Transpl* 2003; **9**: 552-556

S- Editor Xia HHX and Guo SY L- Editor Elsevier HK E- Editor Liu WF